Hoffman E J, Warren E W
University of Michigan Hospital, Ann Arbor.
Clin Pharm. 1993 Sep;12(9):641-56; quiz 699-701.
The mechanism of action, pharmacokinetics, and use of flumazenil in benzodiazepine overdose, as well as in the management of other disease states, are reviewed. Flumazenil interacts at the central benzodiazepine receptor to antagonize or reverse the behavioral, neurologic, and electrophysiologic effects of benzodiazepine agonists and inverse agonists. Flumazenil has been studied for a variety of indications, including as an antidote to benzodiazepine overdose and for awakening of comatose patients, reversal of sedation after surgery and in critically ill patients, and management of hepatic encephalopathy. It improves the level of consciousness in patients with benzodiazepine overdose; however, resedation may occur within one to two hours after administration, so repeated doses or a continuous infusion may be required to maintain therapeutic efficacy. It appears to be effective in reversing sedation induced by midazolam or diazepam, and case reports suggest that it is useful in awakening comatose patients, although its clinical utility is questionable. Flumazenil has proved useful in reversing conscious sedation in critically ill patients, although response may be dose dependent. Animal models indicate that flumazenil is of some benefit in hepatic encephalopathy, but until well-designed clinical trials are conducted, hepatic encephalopathy must be considered an investigational indication for flumazenil. Adverse reactions include CNS manifestations, resedation, cardiovascular effects, seizures, and alterations in intracranial pressure and cerebral perfusion pressure. Hepatic dysfunction results in a substantial change in the pharmacokinetic profile of flumazenil; therefore, dosage adjustment may be necessary in patients with hepatic dysfunction or in those receiving medications that alter flumazenil metabolism. Flumazenil has been shown to reverse sedation caused by intoxication with benzodiazepines alone or benzodiazepines in combination with other agents, but it should not be used when cyclic antidepressant intoxication is suspected. It may be beneficial after surgery when benzodiazepines have been used as part of anesthesia and after a diagnostic or surgical procedure when assessment of CNS function is necessary.
本文综述了氟马西尼在苯二氮䓬类药物过量中毒以及其他疾病状态管理中的作用机制、药代动力学和应用情况。氟马西尼作用于中枢苯二氮䓬受体,拮抗或逆转苯二氮䓬类激动剂和反向激动剂的行为、神经和电生理效应。氟马西尼已针对多种适应症进行了研究,包括作为苯二氮䓬类药物过量中毒的解毒剂、用于唤醒昏迷患者、逆转手术后和重症患者的镇静作用以及治疗肝性脑病。它可提高苯二氮䓬类药物过量中毒患者的意识水平;然而,给药后一到两小时内可能会再次出现镇静,因此可能需要重复给药或持续输注以维持治疗效果。它似乎能有效逆转由咪达唑仑或地西泮引起的镇静作用,病例报告表明它对唤醒昏迷患者有用,尽管其临床实用性存在疑问。氟马西尼已被证明对逆转重症患者的清醒镇静有效,尽管反应可能与剂量有关。动物模型表明氟马西尼对肝性脑病有一定益处,但在进行精心设计的临床试验之前,肝性脑病必须被视为氟马西尼的试验性适应症。不良反应包括中枢神经系统表现、再次镇静、心血管效应、癫痫发作以及颅内压和脑灌注压的改变。肝功能不全导致氟马西尼的药代动力学特征发生重大变化;因此,肝功能不全患者或接受改变氟马西尼代谢药物的患者可能需要调整剂量。氟马西尼已被证明可逆转单独使用苯二氮䓬类药物或苯二氮䓬类药物与其他药物联合中毒引起的镇静作用,但怀疑有环性抗抑郁药中毒时不应使用。在手术中使用苯二氮䓬类药物作为麻醉一部分后以及在诊断或手术操作后需要评估中枢神经系统功能时,它可能有益。